Changes in the <font color="blue">fatty_1</font> <font color="blue">acid_1</font> <font color="blue">composition_1</font> <font color="blue">of_1</font> <font color="blue">the_1</font> <font color="blue">plasma_1</font> <font color="blue">lipid_1</font> <font color="blue">esters_1</font> during lipid - lowering treatment with diet , clofibrate and niceritrol . Reduction of the <font color="blue">proportion_1</font> <font color="blue">of_1</font> <font color="blue">linoleate_1</font> by clofibrate but not by niceritrol . 
<br>
<br> <font color="blue">The_1</font> <font color="blue">fatty_1</font> <font color="blue">acid_1</font> <font color="blue">composition_1</font> <font color="blue">of_1</font> <font color="blue">the_1</font> <font color="blue">plasma_1</font> <font color="blue">lipid_1</font> <font color="blue">esters_1</font> has been studied during lipid - lowering treatment of 95 patients with atherosclerotic disease . During the first two months of the trial only a diet was prescribed . During the ensuing two months either clofibrate or niceritrol , a nicotinic acid ester , was added in a randomized order . During the last two months the second drug was added . The combined treatment with diet , clofibrate and niceritrol caused highly significant <font color="blue">serum_1</font> <font color="blue">lipid_1</font> reductions . <font color="blue">The_1</font> <font color="blue">fatty_1</font> <font color="blue">acid_1</font> <font color="blue">composition_1</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">plasma_1</font> <font color="blue">lipid_1</font> <font color="blue">esters_1</font> was determined in samples from each trial period to measure the degree of dietary adherence . During dietary treatment the relative <font color="blue">content_2</font> <font color="blue">of_2</font> <font color="blue">saturated_4</font> <font color="blue">and_4</font> <font color="blue">monounsaturated_4</font> <font color="blue">fatty_4</font> <font color="blue">acids_4</font> <font color="blue">secreased_1</font> <font color="blue">and_1</font> <font color="blue">the_1</font> <font color="blue">polyunsaturated_4</font> <font color="blue">fatty_4</font> <font color="blue">acids_4</font> <font color="blue">increased_1</font> with an <font color="blue">increasing_1</font> <font color="blue">ratio_2</font> <font color="blue">between_2</font> <font color="blue">pulyunsaturated_2</font> <font color="blue">and_2</font> <font color="blue">saturated_2</font> <font color="blue">fatty_2</font> <font color="blue">acids_2</font> <font color="blue">(_1</font> <font color="blue">P_1</font> <font color="blue">/_1</font> <font color="blue">S_1</font> <font color="blue">ratio_1</font> <font color="blue">)_1</font> in the cholesterol esters and triglycerides . Only <font color="blue">minor_1</font> <font color="blue">changes_1</font> <font color="blue">were_1</font> <font color="blue">seen_1</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">phospholipids_2</font> <font color="blue">._2</font> The changes caused by the diet were partly reversed by clofibrate while niceritrol did not cause any major changes of the <font color="blue">fatty_3</font> <font color="blue">acid_3</font> <font color="blue">composition_3</font> <font color="blue">._3</font> Clofibrate treatment coincided with increasing <font color="blue">amounts_1</font> <font color="blue">of_1</font> <font color="blue">monounsaturated_3</font> <font color="blue">fatty_3</font> <font color="blue">acids_3</font> <font color="blue">,_3</font> especially <font color="blue">oleate_1</font> ( 18 : 1 ) , in the <font color="blue">cholesterol_1</font> <font color="blue">esters_1</font> <font color="blue">,_1</font> <font color="blue">triglycerides_3</font> <font color="blue">and_3</font> <font color="blue">phospholipids_3</font> <font color="blue">while_1</font> <font color="blue">there_1</font> <font color="blue">were_1</font> <font color="blue">significant_1</font> <font color="blue">reductions_1</font> <font color="blue">of_1</font> <font color="blue">the_1</font> <font color="blue">content_3</font> <font color="blue">of_3</font> <font color="blue">linoleic_4</font> <font color="blue">(_1</font> <font color="blue">18_1</font> <font color="blue">:_1</font> <font color="blue">2_1</font> <font color="blue">)_1</font> <font color="blue">acid_2</font> in both the cholesterol esters and triglycerides . The 18 : 2/18 : 1 ratio <font color="blue">decreased_1</font> <font color="blue">significantly_1</font> <font color="blue">in_1</font> <font color="blue">all_1</font> <font color="blue">the_1</font> <font color="blue">lipid_1</font> <font color="blue">esters_1</font> <font color="blue">analyzed_1</font> <font color="blue">._1</font> However , the <font color="blue">P_2</font> <font color="blue">/_2</font> <font color="blue">S_2</font> <font color="blue">ratio_2</font> was not significantly affected , partly because the relative <font color="blue">content_1</font> <font color="blue">of_1</font> <font color="blue">saturated_2</font> <font color="blue">fatty_2</font> <font color="blue">acids_2</font> also tended to decrease during clofibrate treatment . It is concluded that addition of clofibrate treatment to patients who are on a diet enriched with polyunsaturated fats is associated with a <font color="blue">change_1</font> <font color="blue">from_1</font> <font color="blue">polyunsaturated_2</font> <font color="blue">to_2</font> <font color="blue">monounsaturated_2</font> <font color="blue">fatty_2</font> <font color="blue">acids_2</font> <font color="blue">in_2</font> <font color="blue">the_2</font> <font color="blue">plasma_2</font> <font color="blue">lipid_2</font> <font color="blue">esters_2</font> <font color="blue">but_1</font> <font color="blue">does_1</font> <font color="blue">not_1</font> <font color="blue">significantly_1</font> <font color="blue">effect_1</font> <font color="blue">the_1</font> <font color="blue">ratio_2</font> <font color="blue">between_1</font> <font color="blue">polyunsaturated_1</font> <font color="blue">and_1</font> <font color="blue">saturated_1</font> <font color="blue">fatty_1</font> <font color="blue">acids_1</font> <font color="blue">._1</font> The fatty <font color="blue">acid_1</font> <font color="blue">changes_1</font> caused by clofibrate treatment and counteracted by an increased amount of polyunsaturated fat in the diet .